|
1
|
Dong KK, Damaghi N, Kibitel J, Canning MT,
Smiles KA and Yarosh DB: A comparison of the relative antioxidant
potency of L-ergothioneine and idebenone. J Cosmet Dermatol.
6:183–188. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schulz JB, Di Prospero NA and Fischbeck K:
Clinical experience with high-dose IDB in Friedreich ataxia. J
Neurol. 256 Suppl 1:S42–S45. 2009. View Article : Google Scholar
|
|
3
|
Ahmed MA: Neuroprotective effects of
idebenone against pilocarpine-induced seizures: Modulation of
antioxidant status, DNA damage and Na(+), K (+)-ATPase activity in
rat hippocampus. Neurochem Res. 39:394–402. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gutzmann H, Kühl KP, Hadler D and Rapp MA:
Safety and efficacy of idebenone versus tacrine in patients with
Alzheimer's disease: Results of a randomized, double-blind,
parallel-group multicenter study. Pharmacopsychiatry. 35:12–18.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parkinson MH, Schulz JB and Giunti P:
Co-enzyme Q10 and idebenone use in Friedreich's ataxia. J
Neurochem. 126 Suppl 1:S125–S141. 2013. View Article : Google Scholar
|
|
6
|
Rustin P, von Kleist-Retzow JC,
Chantrel-Groussard K, Sidi D, Munnich A and Rötig A: Effect of
idebenone on cardiomyopathy in Friedreich's ataxia: A preliminary
study. Lancet. 354:477–479. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rustin P, Rötig A, Munnich A and Sidi D:
Heart hypertrophy and function are improved by idebenone in
Friedreich's ataxia. Free Radic Res. 36:467–469. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Artuch R, Aracil A, Mas A, Colomé C,
Rissech M, Monrós E and Pineda M: Friedreich's ataxia: Idebenone
treatment in early stage patients. Neuropediatrics. 33:190–193.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hausse AO, Aggoun Y, Bonnet D, Sidi D,
Munnich A, Rötig A and Rustin P: idebenone and reduced cardiac
hypertrophy in Friedreich's ataxia. Heart. 87:346–349. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
La Pean A, Jeffries N, Grow C, Ravina B
and Di Prospero NA: Predictors of progression in patients with
Friedreich ataxia. Mov Disord. 23:2026–2032. 2008.PubMed/NCBI
|
|
11
|
Di Prospero NA, Baker A, Jeffries N and
Fischbeck KH: Neurological effects of high-dose idebenone in
patients with Friedreich's ataxia: A randomised, placebo-controlled
trial. Lancet Neurol. 6:878–886. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tonon C and Lodi R: Idebenone in
Friedreich's ataxia. Expert Opin Pharmacother. 9:2327–2337. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pineda M, Arpa J, Montero R, Aracil A,
Domínguez F, Galván M, Mas A, Martorell L, Sierra C, Brandi N, et
al: idebenone treatment in paediatric and adult patients with
Friedreich ataxia: Long-term follow-up. Eur J Paediatr Neurol.
12:470–475. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Riazi A, Cano SJ, Cooper JM, Bradley JL,
Schapira AH and Hobart JC: Coordinating outcomes measurement in
ataxia research: Do some widely used generic rating scales tick the
boxes? Mov Disord. 21:1396–1403. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu GR, Zhou XY, Lu H, Zhou JW, Li AP, Xu
W, Li JY and Wang CY: Human bone marrow mesenchymal stem cells
express multiple hematopoietic growth factors. Zhongguo Shi Yan Xue
Ye Xue Za Zhi. 11:115–119. 2003.(In Chinese). PubMed/NCBI
|
|
16
|
da Silva Meirelles L, Sand TT, Harman RJ,
Lennon DP and Caplan AI: MSC frequency correlates with blood vessel
density in equine adipose tissue. Tissue Eng Part A. 15:221–229.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Antunes MA, Abreu SC, Cruz FF, Teixeira
AC, Lopes-Pacheco M, Bandeira E, Olsen PC, Diaz BL, Takyia CM,
Freitas IP, et al: Effects of different mesenchymal stromal cell
sources and delivery routes in experimental emphysema. Respir Res.
15:1182014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Barry FP and Murphy JM: Mesenchymal stem
cells: Clinical applications and biological characterization. Int J
Biochem Cell Biol. 36:568–584. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang ZX, Han ZB, Ji YR, Wang YW, Liang L,
Chi Y, Yang SG, Li LN, Luo WF, Li JP, et al: CD106 identifies a
subpopulation of mesenchymal stem cells with unique
immunomodulatory properties. PLoS One. 8:e593542013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Burk J, Gittel C, Heller S, Pfeiffer B,
Paebst F, Ahrberg AB and Brehm W: Gene expression of tendon markers
in mesenchymal stromal cells derived from different sources. BMC
Res Notes. 7:8262014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu H, Qian H, Zhu W, Zhang X, Yan Y, Mao
F, Wang M, Xu H and Xu W: Mesenchymal stem cells relieve fibrosis
of Schistosoma japonicum-induced mouse liver injury. Exp Biol Med
(Maywood). 237:585–592. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Farris P: Idebenone, green tea, and
Coffeeberry extract: New and innovative antioxidants. Dermatol
Ther. 20:322–329. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McDaniel DH, Neudecker BA, DiNardo JC,
Lewis JA II and Maibach HI: Idebenone: A new antioxidant-Part I.
Relative assessment of oxidative stress protection capacity
compared to commonly known antioxidants. J Cosmet Dermatol.
4:10–17. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Haginoya K, Miyabayashi S, Kikuchi M,
Kojima A, Yamamoto K, Omura K, Uematsu M, Hino-Fukuyo N, Tanaka S
and Tsuchiya S: Efficacy of idebenone for respiratory failure in a
patient with Leigh syndrome: A long-term follow-up study. J Neurol
Sci. 278:112–114. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Meier T and Buyse G: Idebenone: An
emerging therapy for Friedreich ataxia. J Neurol. 256 Suppl
1:S25–S30. 2009. View Article : Google Scholar
|
|
26
|
Zs-Nagy I: Chemistry, toxicology,
pharmacology and pharmacokinetics of idebenone: A review. Arch
Gerontol Geriatr. 11:177–186. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gillis JC, Benefield P and McTavish D:
Idebenone. A review of its pharmacodynamic and pharmacokinetic
properties, and therapeutic use in age-related cognitive disorders.
Drugs Aging. 5:133–152. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Suno M and Nagaoka A: Inhibition of lipid
peroxidation by a novel compound (CV-2619) in brain mitochondria
and mode of action of the inhibition. Biochem Biophys Res Commun.
125:1046–1052. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Deng W, Han Q, Liao L, You S, Deng H and
Zhao RC: Effects of allogeneic bone marrow-derived mesenchymal stem
cells on T and B lymphocytes from BXSB mice. DNA Cell Biol.
24:458–463. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Corcione A, Benvenuto F, Ferretti E,
Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi
GL, Pistoia V and Uccelli A: Human mesenchymal stem cells modulate
B-cell functions. Blood. 107:367–372. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yin Z, Chen D, Hu F, Ruan Y, Li J, Wang L,
Xiang Y, Xie L, Wang X, Ichim TE, et al: Cotransplantation with
xenogenetic neonatal porcine sertoli cells significantly prolongs
islet allograft survival in nonimmunosuppressive rats.
Transplantation. 88:339–345. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dufour JM, Dass B, Halley KR, Korbutt GS,
Dixon DE and Rajotte RV: Sertoli cell line lacks the
immunoprotective properties associated with primary Sertoli cells.
Cell Transplant. 17:525–534. 2008. View Article : Google Scholar : PubMed/NCBI
|
